MB
Therapeutic Areas
Ardelyx Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tenapanor (XPHOZAH) | Hyperphosphatemia in chronic kidney disease patients on dialysis | Approved |
| Tenapanor (IBSRELA) | Irritable bowel syndrome with constipation (IBS-C) | Approved |
| RDX013 | Hyperkalemia (elevated potassium) | Phase 2 |
| RDX020 | Type 2 diabetes (as add-on therapy) | Phase 2b |
| Tenapanor | Resistant hypertension | Phase 2 |
Leadership Team at Ardelyx
MR
Michael Raab
President, Chief Executive Officer, and Director
JR
Justin Renz
Chief Financial Officer and Treasurer
LA
Laura A. Williams
Chief Medical Officer
DP
David P. Rosenbaum
Chief Development Officer
RB
Robert Blanks
Senior Vice President, Research
TM
Tersh McCredy
Senior Vice President, Commercial
EG
Elizabeth Grammer
Chief Legal Officer and Corporate Secretary
DM
David Mott
Chairman of the Board
RO
Robert O. Blanks
Director
TC
Todd C. Brady
Director